- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 107218
10-year publication summary
|
2229
|
2456
|
4430
|
6313
|
6708
|
7822
|
9071
|
9783
|
9895
|
7709
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10685 |
1016 |
| The Regents of the University of California | 20195 |
901 |
| Genentech, Inc. | 4014 |
767 |
| F. Hoffmann-La Roche AG | 7946 |
746 |
| Bristol-myers Squibb Company | 4847 |
696 |
| Dana-Farber Cancer Institute, Inc. | 2607 |
683 |
| Board of Regents, The University of Texas System | 5906 |
616 |
| Merck Patent GmbH | 5770 |
518 |
| AstraZeneca AB | 2855 |
514 |
| Memorial Sloan-Kettering Cancer Center | 1968 |
513 |
| The Johns Hopkins University | 5731 |
485 |
| Centre National de La Recherche Scientifique | 10632 |
460 |
| Hoffmann-La Roche Inc. | 3504 |
454 |
| Incyte Corporation | 1035 |
447 |
| Amgen Inc. | 4141 |
445 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2892 |
422 |
| Janssen Pharmaceutica N.V. | 3360 |
408 |
| Pfizer Inc. | 3379 |
406 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3369 |
397 |
| Bayer Pharma AG | 1054 |
393 |
| Other owners | 95931 |